According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
Borghetti, A., Mondi, A., Piccoli, B., Gagliardini, R., Lamonica, S., Ciccarelli, N., et al. (2014). Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 17(4 Suppl. 3), 19817-19817 [10.7448/IAS.17.4.19817].
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
DE LUCA, ANDREA;
2014-01-01
Abstract
According to recent evidence about boosted protease inhibitors (PIs/r)-simplified regimens, the combination of 3TC and DRV/r 800/100 mg could represent a feasible option for optimizing antiretroviral therapy (ART) in treatment-experienced HIV+ patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Borghetti_et_al-2014-Journal_of_the_International_AIDS_Society.pdf
accesso aperto
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
79.86 kB
Formato
Adobe PDF
|
79.86 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/1011877